Eli Lilly announced plans to invest $3 billion to build a manufacturing facility in Katwijk, the Netherlands, to produce its oral GLP‑1 candidate orforglipron and other small‑molecule assets. The plant marks a major capacity expansion as Lilly scales up for oral obesity and metabolic therapies. The site will support Lilly’s push into oral incretin therapeutics at a time when demand for obesity medicines has surged. The investment signals confidence in commercial uptake of oral GLP‑1 modalities and in securing supply chain resilience for high‑volume indications. The announcement is likely to spur further industry planning around capacity, regulatory filings and partnerships as companies race to capture market share in the obesity and metabolic‑disease markets.